Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
SAN DIEGO, Calif. , Dec. 5, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on December 7, 2023 (https://emerginggrowth.com/conference/).
This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to get through as many of them as possible.
"We plan to use this time to discuss our progress and timeline regarding our DuraCAR program as well as update our shareholders on our financial plan," says Dr. David Koos, CEO and Chairman of the Company.
Regen BioPharma, Inc. will be presenting at 3:25 - 3:35 Eastern time on Thursday, December 7, 2023. Please register here to ensure you are able to attend the conference and receive any updates that are released https://goto.webcasts.com/starthere.jsp?ei=1641026&tp_key=4a8f04de2b&sti=rgbp.
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-to-present-at-the-emerging-growth-conference-on-december-7-2023-302005649.html